Nuvectis Pharma’s NXP800 Receives the US FDA’s Orphan Drug Designation to Treat Various ARID1a-Deficient Cancers
Shots:
- The US FDA has granted orphan drug designation to NXP800 for treating AT-rich interactive domain-containing protein 1a (ARID1a) deficient ovarian, fallopian tube & primary peritoneal cancers
- NXP800 is currently under P-Ib trial, with dose escalation part assessing safety at increasing doses & schedules & expansion part estimating efficacy in patients with ARID1a-mutated ovarian clear cell & endometrioid cancers
- NXP800 (oral), a small molecule GCN2 activator is also under investigator-sponsored study for cholangiocarcinoma. It has received the US FDA’s FTD for Pt-resistant, ARID1a-mutated ovarian carcinoma
Ref: Nuvectis Pharma | Image: Nuvectis Pharma
Related News:- Bio-Thera Reports the Regulatory Filing Acceptance for BAT2206 (Biosimilar, Stelara) Across the US and EU
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
